Cargando…
Clinical Experience with Octagam® 10 %, a solvent detergent virus inactivated intravenous immunoglobulin: a Canadian retrospective review of utilization
In Canada, intravenous immune globulin (IVIg) products are licensed for six disease indications, however it has been demonstrated that patients with a number of other conditions also benefit from IVIg. Here we report the routine clinical use of Octagam(®) 10 % across three Canadian institutions. A t...
Autores principales: | Betschel, Stephen D., Warrington, Richard J., Schellenberg, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962395/ https://www.ncbi.nlm.nih.gov/pubmed/27468299 http://dx.doi.org/10.1186/s13223-016-0138-9 |
Ejemplares similares
-
The Inactivation by Organic Solvents and Detergents of Partially Purified Rous I Virus Preparations
por: Drayton, H. A.
Publicado: (1961) -
Efficacy and Safety of Octagam® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy
por: Belmokhtar, Chafké, et al.
Publicado: (2019) -
Timing of infections in patients with primary immunodeficiencies treated with intravenous immunoglobulin (IVIg)
por: Gill, Parwinder K., et al.
Publicado: (2018) -
Octagam(®) for chronic inflammatory demyelinating polyneuropathy: results from three observational studies
por: Wietek, Stefan
Publicado: (2018) -
Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada
por: Gerth, William C, et al.
Publicado: (2014)